Cannabics
Pharmaceuticals Inc. announced today that it has signed an IP Licensing and
Collaboration Agreement with Kalapa Holding of Spain for the production and
distribution of CANNABICS SR medical cannabis products in the Spanish market.
Kalapa Holding is a medical cannabis and hemp grower and distributor in Spain,
with a wide line of cannabinoid based products.
CANNABICS
SR medical cannabis products will be available in strict compliance with
Spanish laws and regulations to certified patients through the “Asociacion
Centro Cannabico de Terapias Naturales,” a registered Spanish entity and
affiliate of Kalapa Holding.
CANNABICS
SR products are slated to be produced and distributed locally in Spain, based
on pure extracts produced from select, high quality and organic medical
cannabis strains cultivated by the Asociacion Centro Cannabico de Terapias
Naturales.
“We are
very excited to launch the collaboration with Kalapa Holding in Spain and thus
offer our line of advanced medical cannabis products to European patients for
the first time,” commented Dr. Zohar Koren, CEO of Cannabics Pharmaceuticals.
Dr. Zohar continued, “The substantial synergy that arises through the
combination of the extensive operational capabilities and outreach of Kalapa
Holding in the Spanish medical cannabis market, combined with our advanced
cannabinoid administration technology, as embedded in the CANNABICS SR line of
products, ensures that this is a long-term and sustainable partnership.”
Cannabics
Pharmaceuticals, Inc. is a rising drug development company with endeavors
focused on the development, marketing and sales of advanced drugs, food
supplements, therapies and administration routes based on the wide range of
active ingredients found in strains of the Cannabis plant. CNBX’s flagship
product, CANNABICS SR, is an IP pending medical cannabis capsule designed for
cancer patients as a palliative care treatment. Cannabics’ proprietary SR
technology provides up to 12 hours of beneficial therapeutic relief. The
product allows for a convenient oral dosing one or two times per day.
Currently, Cannabics is preparing to launch its line of SR products in eligible
US states and EU markets under existing medical cannabis regulatory means. At
the same time, the company is preparing to introduce a series of formal
clinical studies in order to establish the unique medical benefits of its
products for patients suffering from various indications.
For more
information on the company visit www.cannabics.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
Sign up
for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The
Quality Stocks Daily Blog http://blog.qualitystocks.net
The
Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The
Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
No comments:
Post a Comment